Pluvicto

Oncology

prostate cancer microscopic image of adenocarcinoma

After Pluvicto: Alpha radiopharma and prostate cancer

Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.

News

Novartis reveals more data behind Pluvicto expansion bid

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

News

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat

News

Novartis' Pluvicto presents survival benefit for castration-...

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival ben

News

Revamped Novartis highlights top R&D programmes at managemen...

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for growth at a meeting with investors and analysts, which it says will be driven ma

After Pluvicto: Alpha radiopharma and prostate cancer

Novartis reveals more data behind Pluvicto expansion bid

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis' Pluvicto presents survival benefit for castration-...

Revamped Novartis highlights top R&D programmes at managemen...

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Discover a new era of healthcare panel engagement: Grounded ...

Pluvicto

Editor's Picks